Physician profile

Anthony Eclavea

Diagnostic Radiology · Kapolei, HI

NPI 1447319702

$1,513.49

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$141.65

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biocompatibles, INC. $948.91 2019
Bard Peripheral Vascular, INC. $229.71 2021-2023
Stryker Corporation $126.85 2021
Ethicon US, LLC $99.69 2019
Boston Scientific Corporation $35.40 2022-2023 Therasphere Y90 Glass Microspheres 10 Gbq
Angiodynamics, INC. $33.32 2021
Cardiva Medical, INC. $19.96 2023 Cardiva Vascade 6/7f Vcs
Inari Medical, INC. $19.65 2023 Ct Thrombectomy System Kit, Flowtriever Catheter, S

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anthony Eclavea

$1,513.49

in general payments reported 2019-2025

Years
2019-2023
Top company
Biocompatibles, INC.

https://glasscript.com/doctor/717918/anthony-eclavea

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.